Transient leukocytopenia following combination therapy for COVID-19.
Respir Investig
; 60(1): 158-161, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-34649811
ABSTRACT
BACKGROUND:
Combination therapy with dexamethasone, remdesivir, and baricitinib has become a promising treatment for moderate or severe COVID-19; however, we have observed transient leukocytopenia in COVID-19 patients who received combination therapy.METHODS:
Twelve consecutive COVID-19 patients treated with combination therapy were included in this retrospective analysis. Blood cell counts collected at the following three time points were analyzed before the start of therapy (period 1), within 24 h of starting therapy (period 2), and within 48 h of period 2 (period 3).RESULTS:
The leukocyte count significantly decreased in period 2 compared to period 1 and then significantly increased in period 3 without withdrawal of baricitinib. The neutrophil count transiently decreased in period 2 and recovered in period 3.CONCLUSIONS:
Clinicians should be aware of transient leukocytopenia in patients with COVID-19 during the early phase of combination therapy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
COVID-19
/
Leucopenia
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article